SCIENTIFIC ADVISORY COMMITTEE ON ALTERNATIVE TOXICOLOGICAL METHODS (SACATM)
Preliminary Agenda

Hilton Arlington
950 North Stafford Street, Arlington, VA 22203
June 16 – 17, 2011

JUNE 16
8:30 AM  Introductions  Dr. Steven Niemi, Massachusetts General Hospital, SACATM Chair
8:40  Welcome and Opening Remarks  Dr. Linda Birnbaum, NIEHS/NTP
Dr. John Bucher, NIEHS/NTP
Dr. Jodie Kulpa-Eddy, USDA, ICCVAM Chair
9:10  Welcome and NICEATM-ICCVAM Update  Dr. William Stokes, NIEHS/NTP
  • NICEATM-ICCVAM Activities
  • Regulatory Acceptance and Availability of ICCVAM-Recommended Alternative Test Methods
  • Public Comments
  • SACATM Discussion  Dr. Niemi
10.00 BREAK
10:30  Report on Peer Review Panel Meeting: Evaluation of an In Vitro Estrogen Receptor Transcriptional Activation Test Method for Endocrine Disruptor Chemical Screening  Dr. Warren Casey, NIEHS/NTP
  • Introduction and Overview of Proposed Methods and Applications
  • Overview of Panel Report
  • Public Comments
  • SACATM Discussion  Dr. Niemi
12:00 PM LUNCH
1:00  Federal Agency Research, Development, Translation, and Validation Activities Relevant to the NICEATM-ICCVAM Five-Year Plan: NIH Update  Dr. Margaret Snyder, NIH
  • Introduction
  • NIH Research Progress and Priorities TBD
  • SBIR Grants and Contracts  Dr. Daniel Shaughnessy, NIEHS
  • Public Comments
  • SACATM Discussion  Dr. Niemi
2:30 BREAK
3:00  Nominations to ICCVAM (ACTION)  Dr. Kulpa-Eddy
  • Introduction  Dr. Thomas Hartung, Biotest AG
  • In Vitro Pyrogen Assay Validation
  • Public Comments
  • SACATM Discussion and Vote  Dr. Niemi
  • Botulinum In Vitro Assays  Dr. Ward Tucker, Biosentinel Inc.
  • Public Comments
  • SACATM Discussion and Vote  Dr. Niemi
4:30  Report from the ICCVAM Workshop Series on Best Practices for Regulatory Safety Testing  Dr. Jill Merrill, FDA
  • Assessing the Potential for Chemically Induced Eye Injuries  Dr. Joanna Matheson, CPSC, ICCVAM Vice-chair
  • Assessing the Potential for Chemically Induced Allergic Contact Dermatitis  Drs. Eugene Elmore, University of California - Irvine and Michael Olson, GlaxoSmithKline
  • Public Comments
  • SACATM Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Introductions</td>
<td>Dr. Niemi</td>
</tr>
<tr>
<td>8:40</td>
<td>Report and Recommendations from the International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency Testing: State of the Science and Future Directions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Public Comments</td>
<td>Dr. Kula-Eddy</td>
</tr>
<tr>
<td></td>
<td>• SACATM Discussion</td>
<td>Dr. Richard McFarland, FDA</td>
</tr>
<tr>
<td>10:00</td>
<td>BREAK</td>
<td>Dr. Niemi</td>
</tr>
<tr>
<td>10:30</td>
<td>Updates on International Collaborations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Korean Center for the Validation of Alternative Methods</td>
<td>Dr. Soojung Sohn, KoCVAM</td>
</tr>
<tr>
<td></td>
<td>• Health Canada</td>
<td>Mr. Michael Inskip, Health Canada</td>
</tr>
<tr>
<td></td>
<td>• Japanese Center for the Validation of Alternative Methods</td>
<td>Dr. Hajime Kojima, JaCVAM</td>
</tr>
<tr>
<td></td>
<td>• European Centre for the Validation of Alternative Methods</td>
<td>Dr. Joachim Kreysa, ECVAM</td>
</tr>
<tr>
<td>12:00</td>
<td>Other Business</td>
<td>Dr. Niemi</td>
</tr>
<tr>
<td>12:15</td>
<td>ADJOURN</td>
<td>Dr. Niemi</td>
</tr>
</tbody>
</table>

Preliminary Draft June 3, 2011